Key points are not available for this paper at this time.
Letters, Comments, and Corrections1 November 1971Fetal Group C Trisomy After Cytosine Arabinoside and ThioguanineL. HERBERT MAURER, M. D. , R. JACKSON FORCIER, M. D. , O. ROSS MCINTYRE, M. D. , KURT BENIRSCHKE, M. D. L. HERBERT MAURER, M. D. Search for more papers by this author, R. JACKSON FORCIER, M. D. Search for more papers by this author, O. ROSS MCINTYRE, M. D. Search for more papers by this author, KURT BENIRSCHKE, M. D. Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps: //doi. org/10. 7326/0003-4819-75-5-809₂ SectionsAboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail ExcerptIn contrast to the conclusion in the recent letter by Pawliger, McLean, and Noyes in the June 1971 ANNALS OF INTERNAL MEDICINE (p. 1012), we cannot conclude that cytosine arabinoside is a relatively safe drug in the treatment of acute leukemia after the first trimester. We have treated a patient with cytosine arabinoside and thioguanine who was pregnant twice during her treatment. Therapeutic abortions were done both times because of the distinct possibility of fetal abnormalities. The patient, a 24-year-old white married woman, was hospitalized in June 1969 with granulocytopenia, circulating blasts and promyelocytes, lymphadenopathy, splenomegaly, anemia, and thrombocytopenia. She. . . References1. JUBERGGILBERTSALISBURY RER: Trisomy C in an infant with polcystic kidneys and other malformations. J Pediatr 76: 598-603, 1970 CrossrefMedlineGoogle Scholar2. HILTONLEWISTROWELL HIH: C group trisomy in identical twins with acute leukemia. Blood 35: 222-226, 1970 CrossrefMedlineGoogle Scholar This content is PDF only. To continue reading please click on the PDF icon. Author, Article, and Disclosure InformationAffiliations: Department of Obstetrics and Gynecology University of California San Diego School of Medicine La Jolla, Calif. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics Cited ByChemotherapy in pregnancyCancer chemotherapeutic agents as human teratogensCancer and pregnancy: A comprehensive reviewCancer in pregnancy: Gaps, challenges and solutionsCytarabineNeoplastic DiseasesAcute Leukemia during Pregnancy: A Single Institutional Experience with 17 CasesPharmacology of antineoplastic agents in pregnancyPericonceptional exposure to topical 5-fluorouracilAdjuvant chemotherapy in a pregnant patient with endodermal sinus tumor of the ovaryAcute leukemia and pregnancyChromosomal Aberrations in a Newborn Whose Mother Received Cytotoxic Treatment during PregnancyCancer and PreganancyCancer in pregnancyPregnancy outcome following cancer chemotherapyCYTARABINE IN PREGNANCYSALT AND HYPERTENSIONAcute Non-lymphocytic Leukaemia in the Third Trimester of PregnancyAcute leukemia in pregnancy: Transient neonatal myelosuppression after combination chemotherapy in the motherTherapeutic leukopheresis of acute myelo-monocytic leukemia in pregnancyConsequences of acute myelogenous leukemia in early pregnancyPREGNANCY AND LEUKÆMIATHE DOCTOR'S ROLE IN FERTILITY REGULATIONGranulocytic sarcoma. Local presentation of a systemic diseaseTreatment of acute leukemia during pregnancyMaternal and Fetal Effects of Systemic Therapy in the Pregnant Woman with Cancer 1 November 1971Volume 75, Issue 5Page: 809-810KeywordsAnemiaCytosineDrugsPregnancySplenomegalyThioguanineTrisomy Issue Published: 1 November 1971 PDF DownloadLoading. . .
Maurer et al. (Mon,) studied this question.